Literature DB >> 1382316

Regulation by ATP and ADP of CFTR chloride channels that contain mutant nucleotide-binding domains.

M P Anderson1, M J Welsh.   

Abstract

Regulation of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel is unusual in that phosphorylated channels require cytosolic adenosine triphosphate (ATP) to open. The CFTR contains two regions predicted to be nucleotide-binding domains (NBDs); site-directed mutations in each NBD have now been shown to alter the relation between ATP concentration and channel activity, which indicates that ATP stimulates the channel by direct interaction with both NBDs. The two NBDs are not, however, functionally equivalent: adenosine diphosphate (ADP) competitively inhibited the channel by interacting with NBD2 but not by interacting with NBD1. Four cystic fibrosis-associated mutations in the NBDs reduced absolute chloride channel activity, and one mutation also decreased the potency with which ATP stimulates channel activity. Dysfunction of ATP-dependent stimulation through the NBDs may be the basis for defective CFTR chloride channel activity in some cystic fibrosis patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382316     DOI: 10.1126/science.1382316

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  68 in total

Review 1.  CFTR channel gating: incremental progress in irreversible steps.

Authors:  L Csanády; D C Gadsby
Journal:  J Gen Physiol       Date:  1999-07       Impact factor: 4.086

2.  A conditional probability analysis of cystic fibrosis transmembrane conductance regulator gating indicates that ATP has multiple effects during the gating cycle.

Authors:  D J Hennager; M Ikuma; T Hoshi; M J Welsh
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

3.  Inhibition of ATPase, GTPase and adenylate kinase activities of the second nucleotide-binding fold of the cystic fibrosis transmembrane conductance regulator by genistein.

Authors:  C Randak; E A Auerswald; I Assfalg-Machleidt; W W Reenstra; W Machleidt
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

4.  Thirteen cystic fibrosis patients, 12 compound heterozygous and one homozygous for the missense mutation G85E: a pancreatic sufficiency/insufficiency mutation with variable clinical presentation.

Authors:  C Vazquez; G Antiñolo; T Casals; J Dapena; J Elorz; J L Seculi; J Sirvent; R Cabanas; C Soler; X Estivill
Journal:  J Med Genet       Date:  1996-10       Impact factor: 6.318

5.  A mutation in CFTR modifies the effects of the adenylate kinase inhibitor Ap5A on channel gating.

Authors:  Qian Dong; Christoph O Randak; Michael J Welsh
Journal:  Biophys J       Date:  2008-09-19       Impact factor: 4.033

Review 6.  Frontiers in research on cystic fibrosis: understanding its molecular and chemical basis and relationship to the pathogenesis of the disease.

Authors:  Y H Ko; P L Pedersen
Journal:  J Bioenerg Biomembr       Date:  1997-10       Impact factor: 2.945

7.  ATP inhibition and rectification of a Ca2+-activated anion channel in sarcoplasmic reticulum of skeletal muscle.

Authors:  G P Ahern; D R Laver
Journal:  Biophys J       Date:  1998-05       Impact factor: 4.033

8.  The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9.

Authors:  Carol A Bertrand; Shalini Mitra; Sanjay K Mishra; Xiaohui Wang; Yu Zhao; Joseph M Pilewski; Dean R Madden; Raymond A Frizzell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-03-30       Impact factor: 5.464

9.  A neutral variant involved in a complex CFTR allele contributes to a severe cystic fibrosis phenotype.

Authors:  Jérôme Clain; Jacqueline Lehmann-Che; Emmanuelle Girodon; Joanna Lipecka; Aleksander Edelman; Michel Goossens; Pascale Fanen
Journal:  Hum Genet       Date:  2005-03-03       Impact factor: 4.132

10.  State-dependent modulation of CFTR gating by pyrophosphate.

Authors:  Ming-Feng Tsai; Hiroyasu Shimizu; Yoshiro Sohma; Min Li; Tzyh-Chang Hwang
Journal:  J Gen Physiol       Date:  2009-04       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.